Eli Lilly’s next-generation Bruton's tyrosine kinase (BTK) inhibitor, pirtobrutinib, is among the new drugs that the European Medicines Agency has begun reviewing for potential pan-EU marketing approval.
Pirtobrutinib, which Lilly has filed with the EMA for treating mantle cell lymphoma, is an investigational highly selective, non-covalent (reversible)...








